Quanterix Corp (QTRX) stock analysis
Close on Nov 12, 2026Market cap $135.26MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed9 of 30 checks passed
Quanterix passes 9 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 1/6
- Past performance
- 0/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 73.5% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $3.02 is below our fair value estimate of $11.40.
No debt
Quanterix has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
What to watch
Return on equity under 15%
Return on equity was -41.7% over the last twelve months and averaged -19.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -67.8%, below the 10% that usually covers the cost of capital.
Revenue growing under 10% a year
Revenue grew 9.6% a year over the last three fiscal years, short of the 10% we look for.
Elevated bankruptcy risk
The Altman Z-score is -2.64; above 3 is the safe zone and below 1.8 the distress zone.
Valuation3/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Quanterix's price-to-book of 0.65 is below the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 3.17.
Trading below fair value
The share price of $3.02 is below our fair value estimate of $11.40.
Margin of safety over 20%
The price is 73.5% below fair value, more than the 20% cushion we look for.
Growth1/6
Revenue growing under 10% a year
Revenue grew 9.6% a year over the last three fiscal years, short of the 10% we look for.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 13.8% over the last twelve months; the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median is 8.4%.
Guidance lowered
Quanterix lowered its 2026 revenues outlook on Aug 10, 2026.
Gross margin slipping
Gross margin was 44.5% over the last twelve months, against 48.3% a year earlier.
Past performance0/6
Return on equity under 15%
Return on equity was -41.7% over the last twelve months and averaged -19.1% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -67.8%, below the 10% that usually covers the cost of capital.
Return on equity below the industry
Quanterix's return on equity of -41.7% is below the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of 1.1%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin below its 5-year average
Net margin was -75.0% over the last twelve months, against a 5-year average of -54.6%.
Net margin below the industry
Quanterix's net margin of -75.0% is below the Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median of -1.3%.
Financial health5/6
No debt
Quanterix has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 3.09 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -2.64; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Quanterix has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$11.40
The share price is 74% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/B | 2.2× | 1.3× | 3.2× | $10.39 | 50% |
| P/S | 4.0× | 3.9× | 4.0× | $12.40 | 50% |
| Fair value | $11.40 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 1.3
- Laboratory Apparatus and Analytical, Optical, Measuring, and Controlling Instruments median 3.2
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $1.61M
- Value traded per 1% price move
- $386.57K
Downside
High risk
- Typical loss in a bad month
- 38.6%
- Volatility (annualized)
- 94%
- Sharpe ratio, 1 year
- -0.48
- Beta to the S&P 500 (5Y)
- 1.34
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.1% | +9.6% | +10.0% | – | |
| Gross profit | -21.8% | +12.7% | +6.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -18.9% | -34.2% | |
| Return on assets | – | -14.3% | -26.0% | |
| Current ratio | – | 5.52 | 2.84 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Inventory turnover | – | 3.0× | 1.7× | |
| Capex to revenue | 3.0% | 4.5% | 1.9% | |
| Diluted shares | 2M | 30M | 43M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Quanterix generated $227.48M from operations and spent $35.11M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -77.1% | 0.34× | 1.32× | -34.2% |
| FY2024 | -28.0% | 0.33× | 1.23× | -11.3% |
| FY2023 | -23.2% | 0.28× | 1.22× | -8.0% |
| FY2022 | -94.4% | 0.23× | 1.17× | -24.9% |
| FY2021 | -50.2% | 0.29× | 1.19× | -17.1% |
| FY2020 | -36.5% | 0.39× | 1.32× | -18.9% |
| FY2019 | -71.9% | 0.48× | 1.40× | -48.1% |
| FY2018 | -83.8% | 0.47× | 1.49× | -59.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$107.15M
- Cash generatingOperating cash flow above zero-$77.24M
- Return on assets improvedROA up on the prior year-9.0% → -26.4%
- Earnings backed by cashOperating cash flow above net income-$77.24M vs -$107.15M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.66 → 2.84
- No dilutionShare count did not rise38M → 43M
- Gross margin improvedGross margin up on the prior year60.47% → 46.77%
- More efficientAsset turnover rose0.32 → 0.34
See a number that looks wrong?